Masitinib ALS Follow-Up Reported Higher 5-Year Survival
TL;DR: A 2026 medRxiv preprint reanalyzed long-term survivors from the AB10015 ALS trial and reported that masitinib-treated patients had higher 5-year survival than historical benchmarks, but the analysis was post hoc, sponsor-supported, and lacked long-term…
Read article